Every Medicare Part D drug plan sold for 2027 traces its price back to one number the federal government publishes each summer: the national average monthly bid amount. The Centers for Medicare & Medicaid Services set that figure at $296.05 for 2027, up from $239.27 the year before. That single figure works its way through a fixed formula that shapes both the premium the government subsidizes and the premium an insurer ultimately charges a beneficiary.
What the National Average Bid Actually Measures
The bid amount is not a price consumers ever see on a bill. It is an enrollment-weighted average of the bids every Part D plan sponsor submits to CMS each spring for basic prescription drug coverage, meaning plans with larger enrollments carry more weight in the average than smaller plans do. Insurers file these bids months before the coverage year begins, estimating what it will cost them to deliver the standard drug benefit CMS defines.
CMS put the 2027 figure at $296.05 in its Medicare Part D 2027 National Average Monthly Bid Amount fact sheet, published July 28, 2026, a jump of roughly 24 percent over the $239.27 average set for 2026. That average draws on bids filed for both stand-alone drug plans and the drug portion of Medicare Advantage plans that include coverage, the two plan structures that together carry most of Medicare’s Part D enrollment. Because the figure rolls up bids from every plan nationwide, it moves when insurers collectively expect higher drug costs, and it moved sharply this year.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
How the Bid Becomes the Base Beneficiary Premium
The national average bid does not become a premium on its own. CMS derives a separate figure, the base beneficiary premium, as roughly a quarter of the national average bid, adjusted downward for the reinsurance subsidies the government pays plans toward high-cost enrollees’ drug spending. For 2027, that calculation produced a base beneficiary premium of $41.33, up $2.34, or 6 percent, from 2026.
The base beneficiary premium is itself a benchmark, not a bill. According to KFF’s explainer on Part D premiums, it represents the starting point CMS uses before adjusting for what an individual plan actually bid, not the amount any specific enrollee pays.
Why One Insurer’s Premium Can Differ From the Base Number
A plan’s actual premium is built by adjusting the base beneficiary premium for the gap between that plan’s own bid and the national average. A plan that bid below the $296.05 average can end up with a premium below the base beneficiary premium; a plan that bid above it pushes the calculation the other way. On top of that base adjustment, CMS layers in any supplemental premium a plan charges for extra benefits, a late-enrollment penalty for beneficiaries who signed up late, a reduction for Medicare Advantage plans that apply rebate dollars to buy down their drug premium, and a further reduction or elimination for enrollees who qualify for the low-income subsidy.
CMS has not yet published what any individual 2027 plan will charge; insurers finalize and file those numbers later in the year, ahead of the fall enrollment period. The national average bid and the base beneficiary premium set the framework insurers price against, not the final number a beneficiary will see on a specific plan’s summary of benefits.
For someone comparing Part D options this fall, the practical implication is that the national trend does not translate evenly to every plan. A plan sponsor that priced its 2027 bid conservatively could hold its premium close to flat even as the national average climbs, while a sponsor whose bid ran well above $296.05 could see a steeper increase. CMS’s published figures describe the market-wide baseline; only each plan’s own filing, once released, will show where an enrollee’s specific options land.
The Subsidy Program Ending After 2026
Part of why the bid-driven premium climbed as much as it did is a program change already locked in. CMS created the Part D Premium Stabilization Demonstration for the 2025 coverage year, a voluntary arrangement that held down the base beneficiary premium and capped how much participating plans’ premiums could rise year over year. The agency’s July 28, 2026 Parts C and D announcement confirms the demonstration ends at the close of CY2026, returning Part D to what CMS calls traditional market conditions starting in CY2027.
That change removes the ceiling that had been muting premium swings for the plans that opted into it, which is one reason insurers, actuaries and trade coverage of the announcement flagged the jump in the national average bid as a signal of a bumpier pricing year ahead, even before any single plan’s 2027 premium is finalized.
The $2 Threshold Behind Some Enrollees’ Choices
CMS’s fact sheet also set the 2027 de minimis amount at $2. That figure determines whether a beneficiary who receives the low-income subsidy and is auto-enrolled in a benchmark plan gets automatically reassigned to a new plan for the coming year. If a plan’s premium rises by $2 or less above the subsidy-covered amount, the enrollee can stay put without CMS moving them; a bigger jump triggers reassignment unless the beneficiary actively chooses to remain. The de minimis policy is unrelated to the national average bid mechanically, but it comes from the same July 28 release and rides on the same underlying bid data insurers filed for 2027.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- What really happens to your joint savings account when you die?
- Bank statements: how long to keep them and when to toss them



